查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1981685

G蛋白偶聯受體市場：按受體分類、治療領域、應用和最終用戶分類－2026-2032年全球市場預測

G-Protein Coupled Receptors Market by Receptor Class, Therapeutic Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，G 蛋白偶聯受體 (GPCR) 市值將達到 42.3 億美元，到 2026 年將成長至 45.8 億美元，複合年成長率為 9.79%，到 2032 年將達到 81.5 億美元。

主要市場統計數據
基準年 2025 42.3億美元
預計年份：2026年 45.8億美元
預測年份 2032 81.5億美元
複合年成長率 (%) 9.79%

這是一個清晰權威的關於 GPCR 科學和商業化的介紹，將近期技術突破置於治療和轉化背景下進行闡述。

G蛋白偶聯受體（GPCR）在細胞訊號傳導和治療方法的創新中佔據核心地位，也是藥理學上最容易調控的膜蛋白家族之一。過去二十年來，高解析度結構生物學、冷凍電鏡和整合計算建模等技術的進步極大地提升了我們闡明受體結構、配體結合模式和訊號傳導偏差的能力。這些科學突破催生了多種小分子、胜肽、生物製劑以及不依賴特定作用機制的藥物發現平台，進一步推動了針對以往難以靶向的受體亞型的研究。

結構生物學、電腦設計和模態創新如何融合，重新定義 GPCR 標靶藥物發現，並重塑全產業的合作模式。

G蛋白偶聯受體（GPCR）領域正經歷一場變革，這得益於科學、技術和經營模式創新的融合。結構測定方法，特別是冷凍電鏡和先進的X光晶體衍射技術，如今能夠提供GPCR-配體複合物的高解析度圖像，從而加速基於結構的藥物設計和先導化合物的合理最佳化。同時，對偏向性激動作用和變構調節的深入理解，正在拓展治療藥物設計的範圍，從而實現對下游訊號通路更具選擇性的調控，並有可能減少脫靶效應。

我們評估與關稅相關的供應鏈調整和採購環境的波動如何重塑各個相關人員的GPCR研發營運策略。

2025年美國關稅政策的變化對GPCR研發相關的供應鏈、成本結構和籌資策略產生了深遠的波動。這種累積影響在專用設備、試劑和實驗室耗材的採購方面最為明顯，這些耗材通常透過國際供應商採購。進口設備組件和某些特殊化學品的關稅增加，推高了進行高解析度結構分析和大規模篩檢的實驗室的資本支出。因此，採購週期延長，由於各機構需要修改供應商合約以應對成本波動，計劃進度可能會因此而延長。

基於全面細分的洞察，描繪受體生物學、臨床應用、治療重點領域和最終用戶角色，以促進策略優先排序。

嚴謹的細分框架揭示了每個受體類別、治療適應症、開發應用和最終用戶的不同機會和風險特徵。基於受體類別，此領域涵蓋A類視紫質、B類胰泌素、C類代謝型麩胺酸受體、F類捲曲/味覺2受體以及孤兒受體。 A類視紫質再細分為胺基酸受體、趨化素受體、脂質受體、單胺受體、視蛋白受體和胜肽受體等亞類，每種亞類都具有其獨特的協調能力和生物學意義。基於治療領域，該領域的研究活動涵蓋心血管疾病、中樞神經系統疾病、胃腸道疾病、發炎、代謝性疾病、腫瘤、疼痛管理和呼吸系統疾病。腫瘤領域的研究進一步細分為乳癌、大腸癌、白血病、肺癌和攝護腺癌，每種癌症都反映了不同的機制和轉化途徑。

協調科學基礎、監管多樣性和商業化途徑的區域戰略考量，以最佳化全球 GPCR 項目部署。

區域趨勢塑造了投資模式、監管預期和企業發展佈局，進而影響以G蛋白偶聯受體（GPCR）為重點的項目。在美洲，強勁的私人投資、緊密的生物製藥公司網路以及重要的學術研究中心為高水準的轉化研究活動提供了支持。同時，法律規範也不斷演進，優先考慮對高需求治療方法進行快速核准。在歐洲、中東和非洲，研究能力分散在各個學術中心和專業生物技術叢集中，監管差異正在催生區域特有的臨床策略和夥伴關係模式。亞太地區憑藉其快速成長的研發能力、強大的生產能力和日益增多的臨床試驗設施，正成為從早期藥物發現到大規模開發活動等各個環節日益重要的樞紐。

製藥巨頭、創新生物技術公司、學術先驅和專業服務供應商之間的互動如何塑造 GPCR 開發中的競爭優勢。

活躍於G蛋白偶聯受體（GPCR）科學研究開發的關鍵機構包括大型製藥企業、創新生物技術公司、學術機構和專業服務供應商。成熟的製藥公司憑藉其豐富的臨床經驗和全球監管專業知識，持續為後期開發和商業化奠定基礎。同時，靈活的生技公司正推動新型治療方法、First-in-Class標靶和專業平台技術的研發。學術機構和公共研究中心仍然是闡明作用機制和早期標靶檢驗的重要資訊來源，它們常常產生轉化科學成果，從而催生衍生公司和許可機會。

為領導者提供切實有效的建議，以加速 GPCR 創新、增強營運韌性並建立與轉化優先事項一致的夥伴關係。

產業領導者應採取一系列切實可行的措施，充分利用科學發展勢頭，同時降低業務風險。首先，他們應優先投資於能夠顯著縮短轉化研究週期的技術，例如基於結構的藥物設計、先進的生物物理表徵以及人工智慧驅動的配體生成，因為這些技術能夠增強決策早期階段的信心。其次，他們應實現供應商網路多元化，並建立近岸夥伴關係關係，以降低供應鏈中斷和關稅成本壓力帶來的風險，同時檢驗替代試劑和服務供應商，並確保實驗的連續性。

採用透明嚴謹的調查方法，結合專家訪談、文獻整合、結構和臨床資料分析以及基於情境的檢驗。

本研究整合了多種互補的調查方法，以提供可靠且可重複的見解。主要資訊透過對各領域專家的結構化訪談收集，包括學術研究人員、臨床首席研究員和產業研發主管，從而對轉化研究中的科學重點和挑戰進行定性分析。次要研究整合了公開的科學文獻、同行評審文章、專利申請、監管文件和臨床試驗註冊資訊，以梳理技術進步和臨床進展。此外，科學資料庫和資源庫的分析使得我們能夠客觀評估結構生物學領域的里程碑事件和模式多樣化。

簡潔明了且切實可行的結論，將科學進步、實際情況和策略挑戰相結合，以實現 GPCR 計畫的持續成功。

總之，在結構生物學和電腦輔助設計技術的進步以及對訊號傳導複雜性的深入理解的推動下，GPCR領域仍然是治療方法創新的一個極具前景的領域。這些進展拓寬了標靶候選範圍，使得針對從中樞神經系統疾病到腫瘤和代謝性疾病等多種適應症開發更具選擇性的療法成為可能。同時，不斷變化的政策環境和供應鏈趨勢也帶來了營運方面的挑戰，需要策略規劃和靈活的夥伴關係。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 G蛋白偶聯受體市場（按受體類別分類）

  • A類視紫質
    • 胺基酸受體
    • 趨化素受體
    • 脂質受體
    • 單胺受體
    • 視蛋白受體
    • 胜肽受體
  • B類胰泌素
  • C類代謝型麩胺酸受體
  • F級 薯條 / 口味2
  • 孤兒受體

第9章：G蛋白偶聯受體市場：依治療領域分類

  • 心血管疾病
  • 中樞神經系統疾病
  • 消化系統疾病
  • 發炎
  • 代謝性疾病
  • 腫瘤學
    • 乳癌
    • 結腸癌
    • 白血病
    • 肺癌
    • 攝護腺癌
  • 疼痛管理
  • 呼吸系統疾病

第10章：G蛋白偶聯受體市場：依應用領域分類

  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 診斷
  • 藥物發現
  • 臨床前開發

第11章：G蛋白偶聯受體市場：依最終用戶分類

  • 學術研究機構
  • 合約研究機構
  • 診斷檢測實驗室
  • 製藥和生物技術公司

第12章：G蛋白偶聯受體市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：G蛋白偶聯受體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：G蛋白偶聯受體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國G蛋白偶聯受體市場

第16章：中國G蛋白偶聯受體市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abalone Bio, Inc.
  • Abcam PLC
  • Addex Therapeutics
  • Becton, Dickinson and Company
  • BioInvenu,Inc.
  • Cisbio Bioassays SAS
  • Confo Therapeutics
  • Corning Incorporated
  • Crinetics Pharmaceuticals, Inc.
  • Domain Therapeutics SA
  • Enzo Life Sciences, Inc.
  • Escient Pharmaceuticals
  • Eurofins Scientific SE
  • Merck KGaA
  • Molecular Devices, LLC
  • OKYO Pharma, Limited
  • Orion Biotechnology
  • OSE Immunotherapeutics
  • PerkinElmer Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Septerna
  • Sosei Group Corporation
  • Tectonic Therapeutic
  • Teon Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
Product Code: MRR-521BAA36EDBA

The G-Protein Coupled Receptors Market was valued at USD 4.23 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 9.79%, reaching USD 8.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.23 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 8.15 billion
CAGR (%) 9.79%

A clear and authoritative introduction to GPCR science and commercialization that situates recent technological breakthroughs within therapeutic and translational contexts

G-protein coupled receptors (GPCRs) occupy a central position in cell signaling and therapeutic innovation, representing one of the most pharmacologically tractable families of membrane proteins. Over the past two decades, technological advances such as high-resolution structural biology, cryo-electron microscopy, and integrative computational modeling have reshaped our ability to interrogate receptor conformations, ligand binding modes, and signaling bias. These scientific breakthroughs have translated into a diversified pipeline of small molecules, peptides, biologics, and modality-agnostic discovery platforms that increasingly target previously intractable receptor subtypes.

In addition, the maturation of translational tools-ranging from chemoproteomics to advanced imaging and human cellular models-has strengthened the bridge between target validation and clinical development. Consequently, stakeholders across pharma, biotechnology, academic institutions, and contract research organizations are prioritizing GPCR portfolios that promise differentiated efficacy, improved safety profiles, and novel mechanisms of action. As a result, stakeholders are recalibrating investment theses, collaboration models, and go-to-market strategies to capture opportunities spanning traditional therapeutic areas and emerging indications.

How converging structural biology, computational design, and modality innovation are redefining GPCR-targeted discovery and reshaping collaboration models across the sector

The GPCR landscape is undergoing transformative shifts driven by converging scientific, technological, and business model innovations. Structural determination methods, particularly cryo-electron microscopy and advanced X-ray crystallography, now enable high-resolution snapshots of GPCR-ligand complexes, which in turn accelerate structure-based drug design and rational optimization of lead compounds. Meanwhile, the growing understanding of biased agonism and allosteric modulation has expanded the therapeutic design space, enabling more selective modulation of downstream signaling pathways and potentially reducing off-target effects.

Concurrently, the integration of artificial intelligence and machine learning into ligand design and virtual screening workflows is improving hit identification efficiency and enabling the rapid exploration of chemical space. At the same time, modality diversification-such as peptide therapeutics, antibody-based GPCR targeting, and intracellular delivery approaches-broadens the ways in which receptors can be selectively engaged. Commercially, these technological shifts catalyze new partnership structures between biotechs and large pharmaceutical companies, and they encourage vertical collaboration with specialized contract research organizations and academic centers that house unique assay platforms and patient-derived models. As these trends continue, competitive advantage will increasingly accrue to organizations that combine deep mechanistic insight with agile translational capabilities.

Assessing how tariff-induced supply chain adjustments and procurement volatility are reshaping operational strategies for GPCR research and development across stakeholder groups

Policy changes in 2025 relating to United States tariffs have introduced ripples that affect supply chains, cost structures, and sourcing strategies relevant to GPCR research and development. The cumulative impact is most visible in the procurement of specialized equipment, reagents, and laboratory consumables that are often sourced through international suppliers. Increased duties on imported instrumentation components and certain specialty chemicals elevate capital expenditure estimates for laboratories undertaking high-resolution structural studies or large-scale screening campaigns. In turn, project timelines can be extended as procurement windows lengthen and institutions reassess vendor agreements to mitigate cost volatility.

Moreover, tariffs influence the economics of outsourcing preclinical and early clinical work to contract research organizations located outside the United States. Organizations that previously relied on cross-border supply resilience are now reconsidering nearshoring or dual-sourcing strategies to maintain continuity. For multinational collaborations, tariff-driven price adjustments may alter the negotiating dynamics of licensing deals and joint development agreements, with partners seeking to share or offset incremental costs. Importantly, these shifts encourage investment in domestic manufacturing of key reagents and in the validation of alternative suppliers, which can strengthen long-term resilience but require short-term capital and operational reallocation. Overall, the tariff environment underscores the need for strategic procurement planning and scenario-based financial modeling when advancing GPCR programs.

Comprehensive segmentation-driven insights that map receptor biology, clinical applications, therapeutic focus areas, and end-user roles to inform strategic prioritization

A rigorous segmentation framework reveals differentiated opportunity and risk profiles across receptor classes, therapeutic indications, development applications, and end users. Based on receptor class, the landscape encompasses Class A Rhodopsin, Class B Secretin, Class C Metabotropic Glutamate, Class F Frizzled/Taste 2, and orphan receptors; within Class A Rhodopsin, subcategories include amino acid receptors, chemokine receptors, lipid receptors, monoamine receptors, opsin receptors, and peptide receptors, each presenting unique ligandability and biological implications. Based on therapeutic area, activities span cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, inflammation, metabolic disorders, oncology, pain management, and respiratory disorders; oncology-focused work further subdivides into breast cancer, colorectal cancer, leukemia, lung cancer, and prostate cancer, reflecting distinct mechanisms and translational pathways.

Based on application, the ecosystem includes clinical trials, diagnostics, drug discovery, and preclinical development, with clinical trials progressing through Phase I, Phase II, and Phase III pathways that carry different evidentiary and operational demands. Based on end user, the market serves academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, each of which plays discrete roles-from basic target discovery to late-stage development and commercialization. Taken together, this segmentation highlights that strategic priorities and resource allocations should be tailored to receptor biology, therapeutic objectives, and the maturity of the application pipeline, while recognizing that cross-segment collaborations frequently accelerate translational progress.

Regional strategic considerations that reconcile scientific capacity, regulatory diversity, and commercial pathways to optimize global GPCR program deployment

Regional dynamics shape investment patterns, regulatory expectations, and operational footprints that influence GPCR-focused programs. In the Americas, robust private investment, a dense network of biopharma companies, and leading academic centers sustain high levels of translational activity, while regulatory frameworks continue to evolve in ways that prioritize expedited pathways for high-need therapies. In Europe, Middle East & Africa, research strength is distributed across academic hubs and specialized biotech clusters, with regulatory diversity prompting region-specific clinical strategies and partnership models. The Asia-Pacific region combines rapidly expanding R&D capacity with significant manufacturing capabilities and a growing presence of clinical trial sites, making it an increasingly important node for both early-stage discovery and large-scale development activities.

These geographic distinctions inform decisions about where to site key operations, how to structure global development plans, and which regional partnerships to pursue. For example, proximity to specialized assay platforms or patient populations may favor localized collaborations, whereas certain regulatory incentives or cost efficiencies can justify centralized development functions. Thus, effective regional strategies require a granular understanding of local ecosystems, talent pools, reimbursement landscapes, and regulatory pathways, and they often benefit from flexible models that balance global coordination with local execution.

How the interplay among pharmaceutical champions, innovative biotechs, academic pioneers, and specialized service providers is shaping competitive advantage in GPCR development

Leading organizations active in GPCR science and development span large pharmaceutical companies, innovative biotech firms, academic centers, and specialized service providers. Established pharmaceutical companies continue to anchor late-stage development and commercialization through deep clinical experience and global regulatory expertise, while nimble biotech companies advance novel modalities, first-in-class targets, and specialized platform technologies. Academic institutions and public research centers remain critical sources of mechanistic insight and early target validation, often generating the translational science that fuels spinouts and licensing opportunities.

Contract research organizations and diagnostic laboratories provide essential infrastructure for assay development, preclinical testing, and clinical trial execution, enabling sponsors to scale programs rapidly without extending fixed capital commitments. In parallel, a growing cohort of technology providers-focusing on AI-driven discovery, high-throughput screening, single-cell functional assays, and advanced structural biology platforms-are creating complementary capabilities that accelerate hit-to-lead cycles. Strategic partnerships between these actors frequently combine proprietary science with operational scale, and competitive differentiation increasingly derives from integrated value chains that link target biology to clinical execution.

Practical, high-impact recommendations for leaders to accelerate GPCR innovation, shore up operational resilience, and align partnerships with translational priorities

Industry leaders should adopt a set of pragmatic, actionable measures to capitalize on scientific momentum while mitigating operational risks. First, prioritize investment in technologies that materially shorten the translational timeline, such as structure-enabled design, advanced biophysical characterization, and AI-augmented ligand discovery, because these capabilities yield higher confidence at earlier decision points. Second, diversify supplier networks and cultivate nearshore partnerships to reduce vulnerability to supply chain disruptions and tariff-driven cost pressures, while concurrently validating alternative reagents and service providers to maintain experimental continuity.

Third, design modular collaboration frameworks that enable dynamic partnerships with academic labs, biotechs, and CROs, aligning incentives through milestone-based agreements and shared data architectures. Fourth, emphasize translational robustness by incorporating human-relevant models, orthogonal validation methods, and early biomarker strategies that de-risk clinical hypotheses. Fifth, develop portfolio governance that balances high-risk, high-reward targets such as orphan receptors with more de-risked programs grounded in validated receptor classes and therapeutic areas. Taken together, these measures support resilient pipelines that can adapt to scientific advances and policy shifts without sacrificing strategic focus.

Transparent and rigorous research methodology combining expert interviews, literature synthesis, structural and clinical data analysis, and scenario-based validation

This research synthesizes multiple complementary methodologies to deliver robust, reproducible findings. Primary information was gathered through structured interviews with domain experts, including academic investigators, clinical leads, and industry R&D executives, which provided qualitative insight into scientific priorities and translational challenges. Secondary research integrated publicly available scientific literature, peer-reviewed publications, patent filings, regulatory filings, and clinical trial registries to map technological trajectories and clinical progress. In addition, analysis of scientific databases and repositories enabled objective assessment of structural biology milestones and modality diversification.

Analytical techniques included thematic synthesis of expert inputs, cross-validation of findings against independent data sources, and scenario analysis to explore operational and policy contingencies such as tariff impacts. Where appropriate, methodological safeguards-such as triangulation across data types and blinded expert review-were applied to reduce bias and improve the reliability of conclusions. The resulting approach emphasizes transparency in assumptions, traceability of evidence, and a clear linkage between scientific findings and practical business implications, thereby facilitating evidence-based decision-making.

A concise and action-oriented conclusion that synthesizes scientific advances, operational realities, and strategic imperatives for sustained GPCR program success

In conclusion, the GPCR domain remains a fertile ground for therapeutic innovation, driven by advances in structural biology, computational design, and a richer understanding of signaling complexity. These developments expand the repertoire of actionable targets and enable increasingly selective therapeutics across a broad spectrum of indications, from central nervous system disorders to oncology and metabolic disease. At the same time, evolving policy environments and supply chain dynamics introduce operational considerations that demand strategic planning and adaptive partnerships.

Looking ahead, success will favor organizations that integrate mechanistic rigor with translational agility: those that invest in enabling technologies, diversify operational dependencies, and design collaborative models that align scientific discovery with clinical execution. By adopting the strategic recommendations outlined here and grounding decisions in validated evidence, stakeholders can enhance the probability of clinical and commercial success while navigating the practical challenges of a rapidly evolving landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. G-Protein Coupled Receptors Market, by Receptor Class

  • 8.1. Class A Rhodopsin
    • 8.1.1. Amino Acid Receptors
    • 8.1.2. Chemokine Receptors
    • 8.1.3. Lipid Receptors
    • 8.1.4. Monoamine Receptors
    • 8.1.5. Opsin Receptors
    • 8.1.6. Peptide Receptors
  • 8.2. Class B Secretin
  • 8.3. Class C Metabotropic Glutamate
  • 8.4. Class F Frizzled/Taste 2
  • 8.5. Orphan Receptors

9. G-Protein Coupled Receptors Market, by Therapeutic Area

  • 9.1. Cardiovascular Diseases
  • 9.2. Cns Disorders
  • 9.3. Gastrointestinal Disorders
  • 9.4. Inflammation
  • 9.5. Metabolic Disorders
  • 9.6. Oncology
    • 9.6.1. Breast Cancer
    • 9.6.2. Colorectal Cancer
    • 9.6.3. Leukemia
    • 9.6.4. Lung Cancer
    • 9.6.5. Prostate Cancer
  • 9.7. Pain Management
  • 9.8. Respiratory Disorders

10. G-Protein Coupled Receptors Market, by Application

  • 10.1. Clinical Trials
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Diagnostics
  • 10.3. Drug Discovery
  • 10.4. Preclinical Development

11. G-Protein Coupled Receptors Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical And Biotech Companies

12. G-Protein Coupled Receptors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. G-Protein Coupled Receptors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. G-Protein Coupled Receptors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States G-Protein Coupled Receptors Market

16. China G-Protein Coupled Receptors Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abalone Bio, Inc.
  • 17.6. Abcam PLC
  • 17.7. Addex Therapeutics
  • 17.8. Becton, Dickinson and Company
  • 17.9. BioInvenu,Inc.
  • 17.10. Cisbio Bioassays SAS
  • 17.11. Confo Therapeutics
  • 17.12. Corning Incorporated
  • 17.13. Crinetics Pharmaceuticals, Inc.
  • 17.14. Domain Therapeutics SA
  • 17.15. Enzo Life Sciences, Inc.
  • 17.16. Escient Pharmaceuticals
  • 17.17. Eurofins Scientific SE
  • 17.18. Merck KGaA
  • 17.19. Molecular Devices, LLC
  • 17.20. OKYO Pharma, Limited
  • 17.21. Orion Biotechnology
  • 17.22. OSE Immunotherapeutics
  • 17.23. PerkinElmer Inc.
  • 17.24. Promega Corporation
  • 17.25. QIAGEN GmbH
  • 17.26. Septerna
  • 17.27. Sosei Group Corporation
  • 17.28. Tectonic Therapeutic
  • 17.29. Teon Therapeutics, Inc.
  • 17.30. Thermo Fisher Scientific Inc.
  • 17.31. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 191. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 215. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 223. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)